Abstract CT264: Clinical phase II study of SCO-101 - an inhibitor of SRPK1 and ABCG2 - restoring sensitivity to FOLFIRI in metastatic FOLFIRI resistant colorectal cancer patients

Authors: Peter Michael Vestlev, Nicklas L. Roest, Jakob HV Schou, Jan Stenvang, Nils Brünner

Published: 2020-09-04

DOI: 10.1158/1538-7445.am2020-ct264

Source: Full article